TRexBio raises $50 million to advance its immunology pipeline, led by investors including Janus Henderson and Balyasny Asset Management.
Amount Raised
$50 Million
Round Type
Funding Round
South San FranciscoBiotechnologyHealth CareTherapeuticsInvestors
Description
TRex Bio, Inc. announced the closing of an oversubscribed $50 million financing round involving both new and existing investors. The funds will support TRexBio's clinical-stage pipeline of Treg therapeutics, including TRB-061. CEO Johnston Erwin expressed gratitude for the support from healthcare investors
Quick answer
TRex Bio raised $50 Million in a Funding Round round, dated January 27, 2026. Investors: Affinity Asset Advisors, Alexandria Venture Investments, Johnson & Johnson Innovation – Jjdc, Inc., Eli Lilly And Company, Delos Capital, Janus Henderson Investors, Avego Bioscience Capital and Polaris Partners. TRex Bio is based in South San Francisco, California, United States.
- How much did TRex Bio raise?
- TRex Bio raised $50 Million in a Funding Round round on January 27, 2026.
- Who invested in TRex Bio?
- Affinity Asset Advisors, Alexandria Venture Investments, Johnson & Johnson Innovation – Jjdc, Inc., Eli Lilly And Company, Delos Capital, Janus Henderson Investors, Avego Bioscience Capital and Polaris Partners are named as investors in this round.
- What does TRex Bio do?
- TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and..
- Where is TRex Bio based and how big is it?
- TRex Bio is based in South San Francisco, California, United States. Fundz records about 62 employees.
- Who are the decision-makers at TRex Bio?
- Fundz holds 1 contact at TRex Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as TRex Bio that raised within 45 days of this round, from Fundz verified event records.
- Combat Medical raised $3.5M (Series A) on March 12, 2026.
- GenSight Biologics raised $2M (Post-IPO Equity) on March 10, 2026.
- Prolium Bioscience raised $50M (Series A) on March 5, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Os Therapies raised $2M on March 4, 2026.
- Antiverse raised $9.3M (Series A) on March 3, 2026.
Who to call at TRex Bio, and when
A new round usually means TRex Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day TRex Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at TRex Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TRex Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TRex Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
TRex Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.